Standard Operating Procedure for LC-MS Method Development in Analytical Method Development

Department	Analytical Method Development
SOP No.	SOP/AMD/106/2025
Supersedes	SOP/AMD/106/2022
Page No.	Page 1 of 14
Issue Date	19/05/2025
Effective Date	20/05/2025
Review Date	19/05/2026

1. Purpose

This SOP provides a comprehensive procedure for the development of Liquid Chromatography–Mass Spectrometry (LC-MS) methods used for qualitative and quantitative determination of drug substances, degradation products, and impurities in pharmaceutical products.

2. Scope

This procedure applies to all LC-MS method development activities within the Analytical Method Development (AMD) laboratory involving small molecules and selected large molecules where mass-based detection is required.

3. Responsibilities

• Analytical Scientist: Conducts method development, optimizes MS parameters, and documents trial runs.
• Mass Spectrometry Specialist: Provides guidance on ion source configuration, tuning, and scan mode settings.
• QA Officer: Reviews development reports for data integrity and compliance.
• Head – AMD: Approves the finalized method and development summary.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring the LC-MS methods are scientifically sound, reproducible, and suitable for regulatory or internal use.

5. Procedure

5.1 Pre-Development Considerations

1. Review analyte characteristics:
   • Structure, pKa, molecular weight, polarity
   • Known fragmentation patterns or related literature
2. Check prior analytical methods and determine objective (quantification, impurity profiling, metabolite ID).
3. Document all pre-development details in Annexure-1: Method Planning Sheet.

5.2 LC System Configuration

1. Select appropriate LC column (C18, C8, Phenyl, HILIC) based on compound polarity.
2. Set column dimensions (e.g., 150 mm × 4.6 mm, 3–5 µm) and temperature (25–40°C).
3. Choose mobile phase combinations (water/acetonitrile or methanol with 0.1% formic acid or ammonium formate).
4. Perform system suitability on test standards.
5. Record in Annexure-2: Chromatographic Setup Log.

5.3 Mass Spectrometer Setup

1. Configure mass spectrometer:
   • Ionization: ESI or APCI
   • Mode: Positive or Negative
   • Polarity switching if required
2. Infuse analyte to optimize parameters:
   • Capillary voltage
   • Desolvation temperature
   • Gas flow rates (Nebulizer, Drying Gas)
   • Fragmentor and cone voltages
3. Record MS tuning values in Annexure-3: MS Optimization Record.

5.4 Method Development Trials

1. Inject test solution and scan in full-scan MS mode (m/z range 100–1000).
2. Identify molecular ion (M+H)⁺ or (M-H)^–.
3. If quantitative, switch to SIM or MRM mode based on:
   • Precursor ion selection
   • Fragment ion optimization
4. Optimize retention time, peak shape, and resolution.
5. Document all experimental runs in Annexure-4: Development Trial Sheet.

5.5 Data Processing and Evaluation

1. Calculate:
   • Signal-to-noise ratio
   • Retention time consistency
   • Ion suppression or enhancement if matrix involved
2. Check selectivity using blank, placebo, and spiked sample.
3. Establish calibration curve and check linearity (5–7 points).
4. Document observations in Annexure-5: Method Evaluation Summary.

5.6 Final Method Recommendation

1. Include finalized parameters:
   • Column type and dimensions
   • Mobile phase composition and flow rate
   • Injection volume and temperature
   • Ion source settings and scan type
2. Submit full method report with system suitability criteria, chromatograms, and spectra.
3. Obtain QA review and approval from Head – AMD.

6. Abbreviations

• LC-MS: Liquid Chromatography–Mass Spectrometry
• SIM: Selected Ion Monitoring
• MRM: Multiple Reaction Monitoring
• ESI: Electrospray Ionization
• APCI: Atmospheric Pressure Chemical Ionization
• SOP: Standard Operating Procedure

7. Documents

1. Method Planning Sheet – Annexure-1
2. Chromatographic Setup Log – Annexure-2
3. MS Optimization Record – Annexure-3
4. Development Trial Sheet – Annexure-4
5. Method Evaluation Summary – Annexure-5

8. References

• ICH Q2(R1) – Validation of Analytical Procedures
• USP <1225> – Validation of Compendial Procedures
• Instrument Manufacturer’s LC-MS Application Notes

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Method Planning Sheet

Analyte	Molecular Weight	Expected Ion	Polarity	Purpose
Compound X	332.4	[M+H]+	Positive	Impurity Profiling

Annexure-2: Chromatographic Setup Log

Column	Mobile Phase A/B	Flow Rate	Injection Volume
C18, 150×4.6 mm	Water/0.1% FA : ACN	0.6 mL/min	10 µL

Annexure-3: MS Optimization Record

Ion Source	Mode	Capillary Voltage	Desolvation Temp
ESI	Positive	4000 V	350°C

Annexure-4: Development Trial Sheet

Trial No.	Retention Time	Peak Area	S/N Ratio	Comment
1	5.2 min	128934	46	Acceptable

Annexure-5: Method Evaluation Summary

The developed LC-MS method for Compound X showed excellent linearity (r² = 0.9995), precision (RSD < 2%), and detection sensitivity (LOD = 0.5 ng/mL). Finalized parameters were approved for internal qualification studies.

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
04/05/2025	2.0	Incorporated Annexures, MRM selection protocol, tuning log format	Annual Review